


USL311

Cat. No.:	HY-114244		
CAS No.:	1373268-67-7		
Molecular Formula:	C ₂₄ H ₃₄ N ₆ O		
Molecular Weight:	422.57		
Target:	CXCR		
Pathway:	GPCR/G Protein; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (59.16 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.3665 mL	11.8324 mL	23.6647 mL
		5 mM		0.4733 mL	2.3665 mL	4.7329 mL
		10 mM		0.2366 mL	1.1832 mL	2.3665 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	USL311 is a selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 ^[1] .
IC ₅₀ & Target	CXCR4

REFERENCES

[1]. Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA